📊 EVOTF Key Takeaways
Is Evotec SE (EVOTF) a Good Investment?
Unable to conduct fundamental analysis due to unavailable SEC financial data. No income statement, balance sheet, or cash flow metrics are accessible for Evotec SE, preventing assessment of profitability, financial health, or growth quality. Data retrieval failure necessitates neutral rating pending data availability.
Evotec's 2024 fundamentals deteriorated materially: revenue grew only 2% to about €797 million, while gross margin fell to 14.4% from 22.4%, operating loss widened to €142.5 million, and net loss deepened to €196.1 million from €83.9 million. Financial health is not distressed yet because liquidity remains meaningful and operating cash flow stayed positive at €18.2 million, but free cash flow was heavily negative due to elevated capex and the company is under a strategic reset with covenant pressure, which weakens growth quality and near-term profitability.
Why Buy Evotec SE Stock? EVOTF Key Strengths
- No strengths identified
- Large liquidity base with roughly €306.4 million cash and €90.4 million short-term investments, plus current assets nearly 2x current liabilities
- Revenue remained resilient and diversified, with 849 customers, 94% repeat business, and growth in Just-Evotec Biologics
- Balance sheet still shows substantial equity of about €952.5 million despite the loss year
EVOTF Stock Risks: Evotec SE Investment Risks
- Complete absence of financial data from SEC EDGAR
- Unable to assess profitability metrics or trends
- Cannot evaluate financial position, liquidity, or leverage ratios
- No cash flow data available for operational health assessment
- Zero insider activity reporting indicates potential data quality issues
- Profitability worsened sharply in 2024, with gross margin compression and much larger operating and net losses
- Free cash flow remained deeply negative as capex stayed high at about €117.5 million versus only €18.2 million of operating cash flow
- Debt covenant pressure, draw-stop on the revolving credit facility, and ineffective internal controls raise execution and governance risk
Key Metrics to Watch
- Revenue and profitability trends when data becomes available
- Operating cash flow and free cash flow generation
- Balance sheet strength and debt levels
- Gross and operating margins in pharmaceutical sector context
- Gross margin and operating loss improvement, especially in Shared R&D and Just-Evotec Biologics
- Operating cash flow versus capital expenditures and any updates on debt covenant renegotiation/liquidity
Evotec SE (EVOTF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EVOTF Profit Margin, ROE & Profitability Analysis
EVOTF vs Healthcare Sector: How Evotec SE Compares
How Evotec SE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Evotec SE Stock Overvalued? EVOTF Valuation Analysis 2026
Based on fundamental analysis, Evotec SE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Evotec SE Balance Sheet: EVOTF Debt, Cash & Liquidity
EVOTF Revenue Growth, EPS Growth & YoY Performance
EVOTF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Evotec SE (CIK: 0001412558)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EVOTF
What is the AI rating for EVOTF?
Evotec SE (EVOTF) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EVOTF's key strengths?
Claude: . ChatGPT: Large liquidity base with roughly €306.4 million cash and €90.4 million short-term investments, plus current assets nearly 2x current liabilities. Revenue remained resilient and diversified, with 849 customers, 94% repeat business, and growth in Just-Evotec Biologics.
What are the risks of investing in EVOTF?
Claude: Complete absence of financial data from SEC EDGAR. Unable to assess profitability metrics or trends. ChatGPT: Profitability worsened sharply in 2024, with gross margin compression and much larger operating and net losses. Free cash flow remained deeply negative as capex stayed high at about €117.5 million versus only €18.2 million of operating cash flow.
What is EVOTF's revenue and growth?
Evotec SE reported revenue of N/A.
Does EVOTF pay dividends?
Evotec SE does not currently pay dividends.
Where can I find EVOTF SEC filings?
Official SEC filings for Evotec SE (CIK: 0001412558) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EVOTF's EPS?
Evotec SE has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EVOTF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Evotec SE has a SELL rating with 44% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EVOTF stock overvalued or undervalued?
Valuation metrics for EVOTF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EVOTF stock in 2026?
Our dual AI analysis gives Evotec SE a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EVOTF's free cash flow?
Evotec SE's operating cash flow is N/A, with capital expenditures of N/A.
How does EVOTF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).